STANO-PHARM 75

STANO-PHARM 75 (Stanozolol Injection 75 mg/ 1.5 ml) is a white suspension for Intramuscular use. Each 1.5 ml contains Stanozolol 75 mg. 

Anabolic steroids are synthetic derivatives of Testosterone. Stanozolol has been found to increase low-density

lipoproteins and decrease high-density lipoproteins. These changes are not associated with any increase in total cholesterol or triglyceride levels and revert to normal on discontinuation of treatment. Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a deficient or non-functional C1 esterase inhibitor (C1 INH) and clinically characterized by episodes of swelling of the face, extremities, genitalia, bowel wall, and upper respiratory tract. In small clinical studies, Stanozolol was effective in controlling the frequency and severity of attacks of angioedema and in increasing serum levels of C 1 INH and C4. Stanozolol is not effective in stopping HAE attacks while they are under way. The effect of Stanozolol on increasing serum levels of C1 INH and C4 may be related to an increase in protein anabolism.

Hereditary Angioedema: Stanozolol is indicated prophylactically to decrease the frequency and severity of attacks of angioedema.

The use of anabolic steroids may be associated with serious adverse reactions, many of which are dose related:

therefore patients should be placed on the lowest possible effective dose. Stanozolol has been given by intramuscular injection in doses of 50 mg to 100mg every 1 or 3 times per week. The prophylactic dose of Stanozolol to be used prior to dental extraction or other traumatic or stressful situations has not been established and may be substantially larger.

Hepatic: Cholestatic jaundice with rarely, hepatic necrosis and death. Hepatocellular neoplasm's and peliosis hepatis have been reported in association with long term androgenic anabolic steroid. Reversible changes in liver function tests also occur including increased bromsulphalein (BSP) retention and increases in serum bilirubin, glutamic oxaloacetic transaminase (SGOT), and alkaline phosphatase.

Genitourinary System:

In men, Prepubertal: Phallic enlargement and increased frequency of erections.

Postpubertal: Inhibition of testicular functions, testicular atrophy and oligospermia, impotence, chronic priapism,

epididymitis and bladder irritability.

In women: Clitoral enlargement, menstrual irregularities.

In both sexes: increased or decreased libido.

CNS: Habituation, excitation, insomnia, and depression.

Gastrointestinal: Nausea, vomiting, diarrhea.

Hematologic: Bleeding in patients on concomitant anticoagulant therapy.

Breast: Gynecomastia.

Larynx: Deepening of the voice in women.

Hair: Hirsutism and male pattern baldness in women.

Skin: Acne (especially in women and prepubertal boys.)

Skeletal: Premature closure of epiphyses in children.

Fluid and Electrolytes: Edema, retention of serum electrolytes (Sodium, chloride, potassium, phosphate, and

calcium).

An overdose of this medication is unlikely to threaten health. Symptoms of Stanozolol overdose are not known.

Store in cool dry place below 25°C. Protect from light.

México Juárez Farmacéuticos S.A.